Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025
Myriad Genetics (NASDAQ: MYGN), a molecular diagnostic testing and precision medicine company, has scheduled its second quarter 2025 earnings release and conference call for August 5, 2025. The financial results will be released after market close, followed by a conference call at 4:30 PM ET.
Management will discuss the company's Q2 2025 financial performance and provide a business update during the call. Investors can access the live webcast through Myriad's Investor Relations website, while those preferring telephone participation must register to receive dial-in details.
Myriad Genetics (NASDAQ: MYGN), azienda specializzata in test diagnostici molecolari e medicina di precisione, ha programmato la pubblicazione dei risultati finanziari del secondo trimestre 2025 e la conference call per il 5 agosto 2025. I risultati saranno diffusi dopo la chiusura del mercato, seguiti da una conference call alle 16:30 ET.
Durante la chiamata, la direzione discuterà le performance finanziarie del secondo trimestre 2025 e fornirà un aggiornamento sulle attività aziendali. Gli investitori potranno seguire la diretta streaming tramite il sito delle Relazioni con gli Investitori di Myriad, mentre chi preferisce partecipare telefonicamente dovrà registrarsi per ricevere i dettagli di accesso.
Myriad Genetics (NASDAQ: MYGN), empresa de pruebas diagnósticas moleculares y medicina de precisión, ha programado la publicación de sus resultados del segundo trimestre de 2025 y la conferencia telefónica para el 5 de agosto de 2025. Los resultados financieros se darán a conocer después del cierre del mercado, seguidos de una conferencia telefónica a las 4:30 PM ET.
La dirección discutirá el desempeño financiero del segundo trimestre de 2025 y ofrecerá una actualización del negocio durante la llamada. Los inversores podrán acceder a la transmisión en vivo a través del sitio web de Relaciones con Inversores de Myriad, mientras que quienes prefieran participar por teléfono deben registrarse para recibir los detalles de acceso.
Myriad Genetics (NASDAQ: MYGN)는 분자 진단 검사 및 정밀 의학 회사로, 2025년 2분기 실적 발표 및 컨퍼런스 콜을 2025년 8월 5일로 예정하고 있습니다. 재무 결과는 시장 마감 후 발표되며, 이어서 오후 4시 30분(동부시간)에 컨퍼런스 콜이 진행됩니다.
경영진은 통화 중 2025년 2분기 재무 성과를 논의하고 사업 현황을 업데이트할 예정입니다. 투자자들은 Myriad 투자자 관계 웹사이트를 통해 라이브 웹캐스트에 접속할 수 있으며, 전화 참여를 원할 경우 등록하여 접속 정보를 받아야 합니다.
Myriad Genetics (NASDAQ : MYGN), société spécialisée dans les tests diagnostiques moléculaires et la médecine de précision, a programmé la publication des résultats du deuxième trimestre 2025 et la conférence téléphonique pour le 5 août 2025. Les résultats financiers seront publiés après la clôture du marché, suivis d'une conférence téléphonique à 16h30 ET.
La direction discutera des performances financières du deuxième trimestre 2025 et fournira une mise à jour sur les activités lors de l'appel. Les investisseurs pourront accéder à la diffusion en direct via le site des Relations Investisseurs de Myriad, tandis que ceux préférant participer par téléphone doivent s'inscrire pour recevoir les informations de connexion.
Myriad Genetics (NASDAQ: MYGN), ein Unternehmen für molekulare Diagnostik und Präzisionsmedizin, hat die Veröffentlichung der Ergebnisse für das zweite Quartal 2025 und die Telefonkonferenz für den 5. August 2025 geplant. Die Finanzzahlen werden nach Börsenschluss veröffentlicht, gefolgt von einer Telefonkonferenz um 16:30 Uhr ET.
Das Management wird während des Anrufs die finanzielle Leistung des zweiten Quartals 2025 besprechen und ein Unternehmensupdate geben. Investoren können den Live-Webcast über die Investor-Relations-Website von Myriad verfolgen, während diejenigen, die telefonisch teilnehmen möchten, sich registrieren müssen, um die Einwahldaten zu erhalten.
- None.
- None.
SALT LAKE CITY, July 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2025 earnings conference call at 4:30pm ET on Tuesday, Aug. 5, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the second quarter 2025.
A live webcast of the conference call can be accessed on Myriad’s Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call. An archived webcast of the call will be available at investor.myriad.com following the call.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Kate Schraml
(224) 875-4493
PR@myriad.com
FAQ
When will Myriad Genetics (MYGN) report Q2 2025 earnings?
How can investors access Myriad Genetics' Q2 2025 earnings call?
What time is Myriad Genetics' Q2 2025 earnings call?
Where can I find the replay of Myriad Genetics' Q2 2025 earnings call?
